ReviewSeminars in immunology2011
Moving to tolerance: clinical application of T regulatory cells.
Review in Seminars in immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Regulatory T cell therapy in autoimmune and immune-mediated diseases: from basic research to clinical practice and future perspectives.Frontiers in immunology · 2026Review
- Liver-targeted allergen immunotherapy rapidly and safely induces antigen-specific tolerance to treat allergic airway disease in mice.Science translational medicine · 2025Article
- Reduced immunomodulatory metabolite concentrations in peri-transplant fecal samples from heart allograft recipients.Frontiers in transplantation · 2023Article
- Linked sensitization by memory CD4+ T cells prevents costimulation blockade-induced transplantation tolerance.JCI insight · 2022Article
- TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4Advances in experimental medicine and biology · 2021Article
- Review
- Treg expression of CIS suppresses allergic airway inflammation through antagonizing an autonomous TH2 program.Mucosal immunology · 2020Article
- FTY720 Regulates Mitochondria Biogenesis in Dendritic Cells to Prevent Kidney Ischemic Reperfusion Injury.Frontiers in immunology · 2020Article
- Hurdles to Cardioprotection in the Critically Ill.International journal of molecular sciences · 2019Review
- Bioprinting an Artificial Pancreas for Type 1 Diabetes.Current diabetes reports · 2019Review
- Engineering human stellate cells for beta cell replacement therapy promotesMaterials today. Bio · 2019Article
- Intradermal injection of low dose human regulatory T cells inhibits skin inflammation in a humanized mouse model.Scientific reports · 2018Article
- Targeting the epitope spreader Pep19 by naïve human CD45RAJournal of periodontal & implant science · 2017Article
- iPSC-Derived Regulatory Dendritic Cells Inhibit Allograft Rejection by Generating Alloantigen-Specific Regulatory T Cells.Stem cell reports · 2017Article
- Tolerance in liver transplantation: Biomarkers and clinical relevance.World journal of gastroenterology · 2016Review
- Targeting Sirtuin-1 prolongs murine renal allograft survival and function.Kidney international · 2016Article
- Sphingosine 1-Phosphate Receptor 3-Deficient Dendritic Cells Modulate Splenic Responses to Ischemia-Reperfusion Injury.Journal of the American Society of Nephrology : JASN · 2016Article
- T regulatory cell chemokine production mediates pathogenic T cell attraction and suppression.The Journal of clinical investigation · 2016Article
- Targeting Antigens to Dec-205 on Dendritic Cells Induces Immune Protection in Experimental Colitis in Mice.European journal of microbiology & immunology · 2016Article
- TGF-β in tolerance, development and regulation of immunity.Cellular immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Decreasing the incidence of chronic rejection and reducing the need for life-long immunosuppression remain important goals in clinical transplantation. In this article, we will review how regulatory T cells (Treg) came to be recognized as an attractive way to prevent or treat allograft rejection, the ways in which Treg can be manipulated or expanded in vivo, and the potential of in vitro expanded/generated Treg for cellular therapy. We will describe the first regulatory T cell therapies that have been or are in the process of being conducted in the clinic as well as the safety concerns of such therapies and how outcomes may be measured.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.